Literature DB >> 9687873

High-titre, cryostable cell-free varicella zoster virus.

D R Harper1, N Mathieu, J Mullarkey.   

Abstract

Work with varicella-zoster virus has been seriously hampered by the difficulty of preparing high-titre cell free virus, and by the instability of such virus when frozen and thawed. We have evaluated the use of a range of protocols and demonstrate that relatively high titres of 19,000 plaque forming units per millilitre may be recovered after freezing in PBS-sucrose-glutamate-serum buffer (PSGC). In addition, we have shown that the virus obtained by this method gives similar results in neutralisation and antiviral susceptibility assays to that freshly prepared from infected cells, allowing the use of high titre, titrated virus stocks in such assays.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687873     DOI: 10.1007/s007050050364

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

2.  High-level cellular and humoral immune responses in Guinea pigs immunized intradermally with a heat-inactivated varicella-zoster virus vaccine.

Authors:  Julia Sarkadi; Mate Jankovics; Kinga Fodor; Zoltan Kis; Maria Takacs; Ildiko Visontai; Istvan Jankovics; Eva Gonczol
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

3.  Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.

Authors:  Karoline Bleymehl; Jindrich Cinatl; Jonas Schmidt-Chanasit
Journal:  Med Microbiol Immunol       Date:  2011-03-04       Impact factor: 3.402

4.  Targeted Genome Sequencing Reveals Varicella-Zoster Virus Open Reading Frame 12 Deletion.

Authors:  Randall J Cohrs; Katherine S Lee; Addilynn Beach; Bridget Sanford; Nicholas L Baird; Christina Como; Chiharu Graybill; Dallas Jones; Eden Tekeste; Mitchell Ballard; Xiaomi Chen; David Yalacki; Seth Frietze; Kenneth Jones; Tihana Lenac Rovis; Stipan Jonjić; Jürgen Haas; Don Gilden
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

5.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

6.  Varicella-zoster virus and herpes simplex virus 1 can infect and replicate in the same neurons whether co- or superinfected.

Authors:  Anna Sloutskin; Michael B Yee; Paul R Kinchington; Ronald S Goldstein
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

7.  Comprehensive analysis of varicella-zoster virus proteins using a new monoclonal antibody collection.

Authors:  Tihana Lenac Roviš; Susanne M Bailer; Venkata R Pothineni; Werner J D Ouwendijk; Hrvoje Šimić; Marina Babić; Karmela Miklić; Suzana Malić; Marieke C Verweij; Armin Baiker; Orland Gonzalez; Albrecht von Brunn; Ralf Zimmer; Klaus Früh; Georges M G M Verjans; Stipan Jonjić; Jürgen Haas
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

8.  In vitro replication of varicella-zoster virus in human retinal pigment epithelial cells.

Authors:  Jonas Schmidt-Chanasit; Karoline Bleymehl; Holger F Rabenau; Rainer G Ulrich; Jindrich Cinatl; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

9.  Productive vs non-productive infection by cell-free varicella zoster virus of human neurons derived from embryonic stem cells is dependent upon infectious viral dose.

Authors:  Anna Sloutskin; Paul R Kinchington; Ronald S Goldstein
Journal:  Virology       Date:  2013-06-12       Impact factor: 3.616

10.  Enumeration of an extremely high particle-to-PFU ratio for Varicella-zoster virus.

Authors:  John E Carpenter; Ernesto P Henderson; Charles Grose
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.